Castle Biosciences, Inc.

05/25/2026

Thank you to all those who serve. Today and every day, we honor you and remember those who've made the ultimate sacrifice.

05/13/2026

NEXT MONTH: Castle's executive management will present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, at 1:20pm ET.

Details/registration: https://hubs.la/Q04gszsM0

05/12/2026

This calls for a celebration!🎉 Castle's AdvanceAD-Tx test has won the Genomics Innovation Award in the 10th annual MedTech Breakthrough Awards program, which recognizes companies driving meaningful progress and improving patient care across the global health and medical technology industry. This marks the fifth MedTech Breakthrough Award that Castle has earned for our innovative testing solutions.

AdvanceAD-Tx is Castle's clinically validated gene expression profile (GEP) test designed to guide systemic treatment decision making in patients 12 and older with moderate-to-severe atopic dermatitis (AD). Further details: https://hubs.la/Q04gcQLR0

05/12/2026

Gene Expression Profiling (GEP) is a laboratory testing method that measures which genes are being expressed in a cell at any given moment.

Understanding the expression levels of certain genes for a specific type of cancer helps to create a molecular portrait of the cancer. This information can provide a deeper understanding of the biology of a tumor, which can vary from patient to patient, and can be utilized in several ways: to diagnose a disease or condition, to understand response to therapy, or to provide prognostic information, all of which can guide clinical management decisions.

05/07/2026

We would walk forever for a cure! 💙 was proud to support AIM at Melanoma's 20th annual Steps Against Melanoma walk in Galveston, Texas, helping to raise awareness, fund research, and support patients and caregivers every step of the way.

Representing : Camilla Zuckero, Olga Cain, and Carmen Gomez

05/06/2026

JUST RELEASED: Castle Biosciences announces financial results for the 1st quarter ended 3/31/26

Q1 2026 Highlights: Revenue of $83.7 million; Q1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025; raising full-year 2026 revenue guidance to $345-355 million from $340-350 million, as of 3/31/26

View further results and access the webcast archive here: https://hubs.la/Q04fJRBS0

05/06/2026

JOIN US TODAY: Castle will release Q1 2026 financial results via webcast at 4:30 pm ET. Registration/log-in details: https://hubs.la/Q04c9vpT0

05/05/2026

In honor of , Castle continues longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma, and The Sun Bus to advance awareness and education through several community initiatives, including advocacy walks, skin cancer screenings, and patient education programs nationwide.

Press release: https://hubs.la/Q04fvqSM0

05/04/2026

NEW DATA generated by researchers at Mayo Clinic will be presented at Digestive Disease Week® , taking place May 2–5 in Chicago. The findings, featured in two poster presentations, demonstrate how molecular risk stratification with the TissueCypher test can refine risk assessment and directly inform real-world management decisions for patients with Barrett's esophagus.

"The findings presented at DDW 2026 suggest that relying on traditional clinical risk assessment alone may not fully capture a patient's true risk of progression," said Cadman L. Leggett, M.D., gastroenterologist at Mayo Clinic and senior author on both studies. "Molecular risk stratification with TissueCypher can provide more clinically actionable insights by more accurately identifying which patients are truly at higher or lower risk. And we see that translating into real-world changes in how physicians manage patients."

Details: https://hubs.la/Q04flflr0

05/04/2026